Research shows that primary care physicians prescribe preventive therapy for migraine less often than migraine specialists.
Using a migraine disability assessment (MIDAS) score obtained through a patient questionnaire provides additional insight into migraine care, according to a poster presented at ISPOR 2019. The research showed that primary care physicians prescribe preventive therapy less often than migraine specialists.
In the retrospective observational study, patients with severe disability made up almost a quarter of the group and had more complex treatment profiles.
Analysis was conducted on deidentified data from the Practice Fusion electronic health record (EHR) database; Practice Fusion is used primarily in small, independent practices, representing roughly equal portions of primary and specialty care. The study sought to better understand migraine treatment patterns in US real-world ambulatory practice.
Using the EHR, data were collected on adult patients with documented migraine and subsequent MIDAS questionnaire between March 2017 and September 2018.
Patients were required to have 12 months or more of activity in the database to establish a baseline period for patient and clinical characteristics. The study included 2731 patients with migraine with MIDAS data. Overall, 84.5% of the patients were female, with an average age of 46.7 years.
Based on answers to 5 questions about level of headache disability, patients were categorized into 4 groups: grade 1 (little or no disability), grade 2 (mild disability), grade 3 (moderate disability), and grade 4 (severe disability). Use of acute and preventive migraine treatments were described by MIDAS score.
Patient distribution by MIDAS score group was:
Compared with the overall cohort, a larger proportion of patients with severe disability had baseline treatment with acute medications (71.3% vs 67.6%) and preventive medications (70.4% vs 62.0%). Patients with severe disability were more likely to be on 3 or more acute (9.4% vs 7.0%) or 3 or more preventive (17.0% vs 14.5%) therapies.
Primary care physicians had a larger proportion of patients with prior acute therapy than specialists (77.0% vs 56.1%) and a lower proportion of patients with prior preventive therapy (57.7% vs 68.8%). Triptans were the most commonly prescribed acute medication and topiramate was the most commonly prescribed preventive medication.
Another recent study found that patients receiving medications for acute migraine had unmet medical needs.
One limitation of the study, which was funded by Amgen, is that because Practice Fusion is used mostly by small practices, it may not be generalizable to other care settings. In addition, EHR prescription orders show provider intent and do not reflect whether the prescription was picked up in the pharmacy or taken by the patient.
Reference
Chia VM, Thach A, Yusuf A, Kallenbach L, Bogdanov A. Characteristics of migraine patients with migraine disability assessment (MIDAS) scores in real-world clinical practice. Presented at: ISPOR 2019 Annual Meeting, New Orleans, Louisiana; May 18-22, 2019. Poster PND87.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen